Taha Ahmed A, Salem Sara Abdallah Mohamed, Faried Eman Zein El Abdeen, Habib Eman Hosni, Al-Fakharany Reham S, Elgendy Marwa O, Abdelkader Hamdy, Al Fatease Adel, Elkady Maged Salah Eldien
Obstetrics & Gynecology Department, Faculty of Medicine, Beni-Suef University, Beni Suef 62521, Egypt.
Obstetrics and Gynecology Department, Fayoum General Hospital, Fayoum 63513, Egypt.
Medicina (Kaunas). 2025 Apr 7;61(4):679. doi: 10.3390/medicina61040679.
Ovarian cancer is a highly lethal gynecological malignancy and the fifth leading cause of cancer-related deaths. Diagnosis mainly involves gynecological examination and transvaginal ultrasonography. To evaluate the diagnostic performance of the Gynecology Imaging Reporting and Data System (GI-RADS) with regard to its ability to evaluate adnexal masses preoperatively, considering a definitive histopathological diagnosis. This study was approved by the ethics committee, and informed consent was obtained from all the patients. This research was conducted at Beni-suef University Hospital between June 2021 and January 2023 on 100 women who experienced pelvic pain due to an adnexal mass. Our study results revealed that the combination of IV-V GI-RADS had high specificity (92.2%), sensitivity (87%), and a negative predictive value (95.9%), but moderate other diagnostic characteristics for predicting adnexal mass malignancy. The GI-RADS classification system is a reliable method for reporting ovarian masses, with high diagnostic accuracy for predicting malignancy. It aids in patient triage and clinical decision making. To optimize care, it is essential to inform referring clinicians about the objectives of the GI-RADS before its implementation in a treatment plan.
卵巢癌是一种极具致死性的妇科恶性肿瘤,是癌症相关死亡的第五大主要原因。诊断主要包括妇科检查和经阴道超声检查。为了评估妇科影像报告和数据系统(GI-RADS)在术前评估附件包块方面的诊断性能,并考虑最终的组织病理学诊断。本研究经伦理委员会批准,并获得了所有患者的知情同意。本研究于2021年6月至2023年1月在贝尼苏韦夫大学医院对100名因附件包块而出现盆腔疼痛的女性进行。我们的研究结果显示,IV-V级GI-RADS的组合具有高特异性(92.2%)、敏感性(87%)和阴性预测值(95.9%),但在预测附件包块恶性方面的其他诊断特征中等。GI-RADS分类系统是一种可靠的卵巢包块报告方法,对预测恶性具有较高的诊断准确性。它有助于患者分流和临床决策。为了优化治疗,在将GI-RADS纳入治疗计划之前,告知转诊临床医生其目标至关重要。